Skip to main content
SpringerLink
Log in

Overview of Multimodality Therapy

  • Chapter
Multimodality Management of Borderline Resectable Pancreatic Cancer

  • 874 Accesses

Abstract

Pancreatic cancer is the fourth leading cause of cancer death in the USA. However, in the last decade, there has been considerable progress in the understanding and treatment of this disease and we are starting to see an impact on survival and quality of life. Chemotherapeutic and surgical options have increased, and refinements in classification and staging to reflect both the biology of these cancers, and the critical interface between these tumors and the adjacent mesenteric and hepatic vasculature, have been proposed. Modern treatment has, of necessity, evolved into a multidisciplinary, multimodality exercise and choices regarding the type and sequencing of therapeutic modalities are now much more complex. Borderline resectable and locally advanced cancers are particularly challenging in this regard as all available modalities will usually be employed at some time during treatment, and goals of therapy will frequently need to be adjusted. Discussion of every patient in a multidisciplinary cancer conference or clinic has become essential to establishing appropriate care plans, and the composition and conduct of such meetings has been analyzed and defined. Academic productivity is also enhanced by this multidisciplinary approach, and the educational component is valuable both for experienced personnel and trainees. Future progress will add to the complexity of care for these challenging patients as molecular and genetic data become increasingly detailed, and biologics, vaccines, and immunotherapies are incorporated into treatment. Collaboration and connectivity between providers from all disciplines of care will be ever more critical to providing optimal results.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1727–33.

    Article  PubMed  Google Scholar 

  2. Tempero M, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, Kim P, et al. Pancreatic adenocarcinoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007;5(10):998–1033.

    PubMed  Google Scholar 

  3. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13(8):1035–46.

    Article  PubMed  Google Scholar 

  4. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206(5):833–46. discussion 46–8.

    Article  PubMed  Google Scholar 

  5. Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20(8):2787–95.

    Article  PubMed  Google Scholar 

  6. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607–20.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605–17.

    Article  CAS  PubMed  Google Scholar 

  8. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson 3rd AB, Casper ES, et al. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10(6):703–13.

    PubMed Central  CAS  PubMed  Google Scholar 

  9. Cassinotto C, Mouries A, Lafourcade JP, Terrebonne E, Belleannee G, Blanc JF, et al. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. Radiology. 2014;273(1):108–16.

    Article  PubMed  Google Scholar 

  10. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749–56.

    Article  PubMed  Google Scholar 

  11. Dholakia A. Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationship. J Radiat Oncol. 2013;2:413–25.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Croome KP, Farnell MB, Que FG, Reid-Lombardo KM, Truty MJ, Nagorney DM, et al. Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches? Ann Surg. 2014;260(4):633–8. discussion 8–40.

    Article  PubMed  Google Scholar 

  13. Kooby DA, Hawkins WG, Schmidt CM, Weber SM, Bentrem DJ, Gillespie TW, et al. A multicenter analysis of distal pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate? J Am Coll Surg. 2010;210(5):779–85. 86–7.

    Article  PubMed  Google Scholar 

  14. Baker MS, Sherman KL, Stocker S, Hayman AV, Bentrem DJ, Prinz RA, et al. Defining quality for distal pancreatectomy: does the laparoscopic approach protect patients from poor quality outcomes? J Gastrointest Surg. 2013;17(2):273–80.

    Article  PubMed  Google Scholar 

  15. Wang J, Estrella JS, Peng L, Rashid A, Varadhachary GR, Wang H, et al. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012;118(15):3801–11.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Christians KK, Pilgrim CH, Tsai S, Ritch P, George B, Erickson B, et al. Arterial resection at the time of pancreatectomy for cancer. Surgery. 2014;155(5):919–26.

    Article  PubMed  Google Scholar 

  17. Ghaferi AA, Birkmeyer JD, Dimick JB. Complications, failure to rescue, and mortality with major inpatient surgery in medicare patients. Ann Surg. 2009;250(6):1029–34.

    Article  PubMed  Google Scholar 

  18. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899–903.

    Article  CAS  PubMed  Google Scholar 

  19. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–82. discussion 82–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Hammel P, Huguet F, Van Laethem J-L, Goldstein D, Glimelius B, Artru P, et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. ASCO Meeting Abstr. 2013;31(15 suppl):LBA4003.

    Google Scholar 

  21. Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011;18(5):1319–26.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Morganti AG, Falconi M, van Stiphout RG, Mattiucci GC, Alfieri S, Calvo FA, et al. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014;90(4):911–7.

    Article  PubMed  Google Scholar 

  23. Reese AS, Lu W, Regine WF. Utilization of intensity-modulated radiation therapy and image-guided radiation therapy in pancreatic cancer: is it beneficial? Semin Radiat Oncol. 2014;24(2):132–9.

    Article  PubMed  Google Scholar 

  24. Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121:1128–37.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Thompson RF, Mayekar SU, Zhai H, Both S, Apisarnthanarax S, Metz JM, et al. A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas. Med Phys. 2014;41(8):081711.

    Article  PubMed  Google Scholar 

  26. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 1996;73(1):101–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol. 2008;61(1):167–75.

    Article  CAS  PubMed  Google Scholar 

  28. Conroy T, Paillot B, Francois E, Bugat R, Jacob JH, Stein U, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer—a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol. 2005;23(6):1228–36.

    Article  CAS  PubMed  Google Scholar 

  29. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.

    Article  CAS  Google Scholar 

  30. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–6.

    Article  CAS  PubMed  Google Scholar 

  31. Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist. 2011;16(10):1397–402.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res. 2004;10(20):6956–61.

    Article  CAS  PubMed  Google Scholar 

  33. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009;136(1):187–95.

    Article  PubMed  Google Scholar 

  34. Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, et al. Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110(51):20723–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  35. Heinemann V, Reni M, Ychou M, Richel DJ, Macarulla T, Ducreux M. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat Rev. 2014;40(1):118–28.

    Article  CAS  PubMed  Google Scholar 

  36. Amedei A, Niccolai E, Prisco D. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Hum Vaccin Immunother. 2014;10:3354–68.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, et al. Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015;33:1325–33.

    Article  CAS  PubMed  Google Scholar 

  38. Tian H, Mori H, Matsumoto S, Yamada Y, Kiyosue H, Ohta M, et al. Extrapancreatic neural plexus invasion by carcinomas of the pancreatic head region: evaluation using thin-section helical CT. Radiat Med. 2007;25(4):141–7.

    Article  PubMed  Google Scholar 

  39. Ikuta Y, Takamori H, Ikeda O, Tanaka H, Sakamoto Y, Hashimoto D, et al. Detection of liver metastases secondary to pancreatic cancer: utility of combined helical computed tomography during arterial portography with biphasic computed tomography-assisted hepatic arteriography. J Gastroenterol. 2010;45(12):1241–6.

    Article  PubMed  Google Scholar 

  40. Vachiranubhap B, Kim YH, Balci NC, Semelka RC. Magnetic resonance imaging of adenocarcinoma of the pancreas. Top Magn Reson Imaging. 2009;20(1):3–9.

    Article  PubMed  Google Scholar 

  41. Cuneo KC, Chenevert TL, Ben-Josef E, Feng MU, Greenson JK, Hussain HK, et al. A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Transl Oncol. 2014;7(5):644–9.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Farma JM, Santillan AA, Melis M, Walters J, Belinc D, Chen DT, et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol. 2008;15(9):2465–71.

    Article  PubMed  Google Scholar 

  43. Wahl RL, Herman JM, Ford E. The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. Semin Radiat Oncol. 2011;21(2):88–100.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Sendler A, Avril N, Helmberger H, Stollfuss J, Weber W, Bengel F, et al. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg. 2000;24(9):1121–9.

    Article  CAS  PubMed  Google Scholar 

  45. Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, Lu DS, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology. 2014;270(1):248–60.

    Article  PubMed  Google Scholar 

  46. Gomez-Mateo C. Pathology handling of pancreatoduodenectomy specimens: approaches and controversies. World J Gastroenterol. 2012;6(9):351–9.

    Google Scholar 

  47. Chatterjee D, Katz MH, Rashid A, Varadhachary GR, Wolff RA, Wang H, et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. 2012;118(12):3182–90.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Luz LP, Al-Haddad MA, DeWitt JA. EUS-guided celiac plexus interventions in pancreatic cancer pain: an update and controversies for the endosonographer. Endosc Ultrasound. 2014;3(4):213–20.

    Article  PubMed Central  PubMed  Google Scholar 

  49. Haapamaki C, Seppanen H, Udd M, Juuti A, Halttunen J, Kiviluoto T, et al. Preoperative biliary decompression preceding pancreaticoduodenectomy with plastic or self-expandable metallic stent. Scand J Surg. 2015;104:79–85.

    Article  CAS  PubMed  Google Scholar 

  50. Shah A, Fehmi A, Savides TJ. Increased rates of duodenal obstruction in pancreatic cancer patients receiving modern medical management. Dig Dis Sci. 2014;59(9):2294–8.

    Article  PubMed  Google Scholar 

  51. Tonozuka R, Itoi T, Sofuni A, Itokawa F, Moriyasu F. Endoscopic double stenting for the treatment of malignant biliary and duodenal obstruction due to pancreatic cancer. Dig Endosc. 2013;25 Suppl 2:100–8.

    Article  PubMed  Google Scholar 

  52. Hamada T, Isayama H, Nakai Y, Kogure H, Yamamoto N, Kawakubo K, et al. Transmural biliary drainage can be an alternative to transpapillary drainage in patients with an indwelling duodenal stent. Dig Dis Sci. 2014;59(8):1931–8.

    Article  CAS  PubMed  Google Scholar 

  53. Zenz M, Kurz-Muller K, Strumpf M, May B. The anterior sonographic-guided celiac plexus blockade. Review and personal observations. Anaesthesist. 1993;42(4):246–55.

    CAS  PubMed  Google Scholar 

  54. Alden D, Dudiy Y, Nassiri N, Friedland RJ, Amatulle P, Rosen RJ. Direct percutaneous transhepatic portomesenteric venous stenting in management of locally advanced pancreatic cancer. Am J Clin Oncol. 2015;38:127–9.

    Article  CAS  PubMed  Google Scholar 

  55. Kauffman CR, Mahvash A, Kopetz S, Wolff RA, Ensor J, Wallace MJ. Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy. Cancer. 2008;112(10):2283–8.

    Article  CAS  PubMed  Google Scholar 

  56. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16(4):836–47.

    Article  PubMed Central  PubMed  Google Scholar 

  57. Visser BC, Ma Y, Zak Y, Poultsides GA, Norton JA, Rhoads KF. Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes. HPB (Oxford). 2012;14(8):539–47.

    Article  Google Scholar 

  58. Bilimoria KY, Bentrem DJ, Lillemoe KD, Talamonti MS, Ko CY. Assessment of pancreatic cancer care in the United States based on formally developed quality indicators. J Natl Cancer Inst. 2009;101(12):848–59.

    Article  PubMed Central  PubMed  Google Scholar 

  59. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246(2):173–80.

    Article  PubMed Central  PubMed  Google Scholar 

  60. Pfeiffer SI, Naglieri JA. An investigation of multidisciplinary team decision-making. J Learn Disabil. 1983;16(10):588–90.

    Article  CAS  PubMed  Google Scholar 

  61. Ruhstaller T, Roe H, Thurlimann B, Nicoll JJ. The multidisciplinary meeting: an indispensable aid to communication between different specialities. Eur J Cancer. 2006;42(15):2459–62.

    Article  PubMed  Google Scholar 

  62. Hwang RF, Wang H, Lara A, Gomez H, Chang T, Sieffert N, et al. Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer. Ann Surg Oncol. 2008;15(5):1356–66.

    Article  PubMed  Google Scholar 

  63. Chang JH, Vines E, Bertsch H, Fraker DL, Czerniecki BJ, Rosato EF, et al. The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. Cancer. 2001;91(7):1231–7.

    Article  CAS  PubMed  Google Scholar 

  64. Oxenberg J, Papenfuss W, Esemuede I, Attwood K, Simunovic M, Kuvshinoff B, et al. Multidisciplinary cancer conferences for gastrointestinal malignancies result in measureable treatment changes: a prospective study of 149 consecutive patients. Ann Surg Oncol. 2015;22(5):1533–9.

    Article  PubMed  Google Scholar 

  65. Wright FC, De Vito C, Langer B, Hunter A. Multidisciplinary cancer conferences: a systematic review and development of practice standards. Eur J Cancer. 2007;43(6):1002–10.

    Article  CAS  PubMed  Google Scholar 

  66. Gatcliffe TA, Coleman RL. Tumor board: more than treatment planning—a 1-year prospective survey. J Cancer Educ. 2008;23(4):235–7.

    Article  PubMed  Google Scholar 

  67. Sarff M, Rogers W, Blanke C, Vetto JT. Evaluation of the tumor board as a Continuing Medical Education (CME) activity: is it useful? J Cancer Educ. 2008;23(1):51–6.

    Article  PubMed  Google Scholar 

  68. Piorkowski RJ. The value of a well-designed tumor board. Conn Med. 2001;65(1):35–6.

    CAS  PubMed  Google Scholar 

  69. Rosenblum ML, Mikkelsen T. Developing a brain tumor center. J Neurooncol. 2004;69(1–3):169–80.

    Article  PubMed  Google Scholar 

  70. Haier J, Bergmann KO. Medicolegal aspects of tumor boards. Chirurg. 2013;84(3):225–30.

    Article  CAS  PubMed  Google Scholar 

  71. Sundi D, Cohen JE, Cole AP, Neuman BP, Cooper J, Faisal FA, et al. Establishment of a new prostate cancer multidisciplinary clinic: Format and initial experience. Prostate. 2015;75(2):191–9.

    Article  PubMed  Google Scholar 

  72. Walter C, Mellor JD, Rice C, Kirsa S, Ball D, Duffy M, et al. Impact of a specialist clinical cancer pharmacist at a multidisciplinary lung cancer clinic. Asia Pac J Clin Oncol. 2014;[Epub ahead of print].

    Google Scholar 

  73. Pawlik TM, Laheru D, Hruban RH, Coleman J, Wolfgang CL, Campbell K, et al. Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol. 2008;15(8):2081–8.

    Article  PubMed Central  PubMed  Google Scholar 

  74. Stevenson MM, Irwin T, Lowry T, Ahmed MZ, Walden TL, Watson M, et al. Development of a virtual multidisciplinary lung cancer tumor board in a community setting. J Oncol Pract. 2013;9(3):e77–80.

    Article  PubMed Central  PubMed  Google Scholar 

  75. Shea CM, Teal R, Haynes-Maslow L, McIntyre M, Weiner BJ, Wheeler SB, et al. Assessing the feasibility of a virtual tumor board program: a case study. J Healthc Manag. 2014;59(3):177–93.

    PubMed Central  PubMed  Google Scholar 

  76. Salami AC, Barden GM, Castillo DL, Hanna M, Petersen NJ, Davila JA, et al. Establishment of a Regional Virtual Tumor Board program to improve the process of care for patients with hepatocellular carcinoma. J Oncol Pract. 2014;[Epub ahead of print].

    Google Scholar 

  77. Delaney G, Jacob S, Iedema R, Winters M, Barton M. Comparison of face-to-face and videoconferenced multidisciplinary clinical meetings. Australas Radiol. 2004;48(4):487–92.

    Article  CAS  PubMed  Google Scholar 

  78. Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, et al. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. Oncologist. 2014;19(6):631–6.

    Article  PubMed Central  PubMed  Google Scholar 

  79. Fazal S, Saif MW. Supportive and palliative care of pancreatic cancer. JOP. 2007;8(2):240–53.

    PubMed  Google Scholar 

  80. Johansen ML, Holtedahl KA, Rudebeck CE. A doctor close at hand: how GPs view their role in cancer care. Scand J Prim Health Care. 2010;28(4):249–55.

    Article  PubMed Central  PubMed  Google Scholar 

  81. Borgsteede SD, Deliens L, van der Wal G, Francke AL, Stalman WA, van Eijk JT. Interdisciplinary cooperation of GPs in palliative care at home: a nationwide survey in The Netherlands. Scand J Prim Health Care. 2007;25(4):226–31.

    Article  PubMed Central  PubMed  Google Scholar 

  82. Johansson B, Berglund G, Hoffman K, Glimelius B, Sjoden PO. The role of the general practitioner in cancer care and the effect of an extended information routine. Scand J Prim Health Care. 2000;18(3):143–8.

    Article  CAS  PubMed  Google Scholar 

  83. Thomas C, Morris SM, Harman JC. Companions through cancer: the care given by informal carers in cancer contexts. Soc Sci Med. 2002;54(4):529–44.

    Article  PubMed  Google Scholar 

  84. Sherman DW, McGuire DB, Free D, Cheon JY. A pilot study of the experience of family caregivers of patients with advanced pancreatic cancer using a mixed methods approach. J Pain Symptom Manage. 2014;48(3):385–99.e1–2.

    Google Scholar 

  85. Petrin K, Bowen DJ, Alfano CM, Bennett R. Adjusting to pancreatic cancer: perspectives from first-degree relatives. Palliat Support Care. 2009;7(3):281–8.

    Article  PubMed  Google Scholar 

  86. Northouse L, Williams AL, Given B, McCorkle R. Psychosocial care for family caregivers of patients with cancer. J Clin Oncol. 2012;30(11):1227–34.

    Article  PubMed  Google Scholar 

  87. Vanderwerker LC, Laff RE, Kadan-Lottick NS, McColl S, Prigerson HG. Psychiatric disorders and mental health service use among caregivers of advanced cancer patients. J Clin Oncol. 2005;23(28):6899–907.

    Article  PubMed Central  PubMed  Google Scholar 

  88. Baquet CR, Commiskey P, Daniel Mullins C, Mishra SI. Recruitment and participation in clinical trials: socio-demographic, rural/urban, and health care access predictors. Cancer Detect Prev. 2006;30(1):24–33.

    Article  PubMed Central  PubMed  Google Scholar 

  89. Merkow RP, Bilimoria KY, Tomlinson JS, Paruch JL, Fleming JB, Talamonti MS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260(2):372–7.

    Article  PubMed  Google Scholar 

  90. Brown KM, Siripurapu V, Davidson M, Cohen SJ, Konski A, Watson JC, et al. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg. 2008;195(3):318–21.

    Article  CAS  PubMed  Google Scholar 

  91. Stokes JB, Nolan NJ, Stelow EB, Walters DM, Weiss GR, de Lange EE, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol. 2011;18(3):619–27.

    Article  PubMed  Google Scholar 

  92. Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, et al. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010;101(7):587–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  93. Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014;19(3):266–74.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  94. Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, Gibson MK, et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol. 2013;108(4):236–41.

    Article  CAS  PubMed  Google Scholar 

  95. Kunzmann V, Herrmann K, Bluemel C, Kapp M, Hartlapp I, Steger U. Intensified neoadjuvant chemotherapy with nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in a patient with locally advanced unresectable pancreatic cancer. Case Rep Oncol. 2014;7(3):648–55.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  96. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267.

    Google Scholar 

  97. Sahora K, Kuehrer I, Eisenhut A, Akan B, Koellblinger C, Goetzinger P, et al. NeoGemOx: gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery. 2011;149(3):311–20.

    Article  PubMed  Google Scholar 

  98. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77.

    Article  CAS  PubMed  Google Scholar 

  99. Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32(6):504–12.

    Article  PubMed  Google Scholar 

  100. Springett GM. Novel pancreatic cancer vaccines could unleash the army within. Cancer Control. 2014;21(3):242–6.

    PubMed  Google Scholar 

  101. Sho M, Akahori T, Tanaka T, Kinoshita S, Tamamoto T, Nomi T, et al. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. J Hepatobiliary Pancreat Sci. 2013;20(2):197–205.

    Article  PubMed  Google Scholar 

  102. Cho SW, Tzeng CW, Johnston WC, Cassera MA, Newell PH, Hammill CW, et al. Neoadjuvant radiation therapy and its impact on complications after pancreaticoduodenectomy for pancreatic cancer: analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). HPB (Oxford). 2014;16(4):350–6.

    Article  PubMed Central  Google Scholar 

  103. Tzeng CW, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolff RA, et al. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014;18(1):16–24; discussion-5.

    Article  PubMed  Google Scholar 

  104. Araujo RL, Gaujoux S, Huguet F, Gonen M, D’Angelica MI, DeMatteo RP, et al. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis. HPB (Oxford). 2013;15(8):574–80.

    Article  Google Scholar 

  105. Scaife CL, Hewitt KC, Mone MC, Hansen HJ, Nelson ET, Mulvihill SJ. Comparison of intraoperative versus delayed enteral feeding tube placement in patients undergoing a Whipple procedure. HPB (Oxford). 2014;16(1):62–9.

    Article  Google Scholar 

  106. Crippa S, Tamburrino D, Partelli S, Salvia R, Germenia S, Bassi C, et al. Total pancreatectomy: indications, different timing, and perioperative and long-term outcomes. Surgery. 2011;149(1):79–86.

    Article  PubMed  Google Scholar 

  107. Matsumoto J, Traverso LW. Exocrine function following the whipple operation as assessed by stool elastase. J Gastrointest Surg. 2006;10(9):1225–9.

    Article  PubMed  Google Scholar 

  108. Trang T, Chan J, Graham DY. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century. World J Gastroenterol. 2014;20(33):11467–85.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  109. von Haehling S, Anker SD. Treatment of cachexia: an overview of recent developments. J Am Med Dir Assoc. 2014;15(12):866–72.

    Article  Google Scholar 

  110. Ruiz Garcia V, Lopez-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;3:CD004310.

    Google Scholar 

  111. Mueller TC, Burmeister MA, Bachmann J, Martignoni ME. Cachexia and pancreatic cancer: are there treatment options? World J Gastroenterol. 2014;20(28):9361–73.

    PubMed Central  PubMed  Google Scholar 

  112. Armstrong T, Strommer L, Ruiz-Jasbon F, Shek FW, Harris SF, Permert J, et al. Pancreaticoduodenectomy for peri-ampullary neoplasia leads to specific micronutrient deficiencies. Pancreatology. 2007;7(1):37–44.

    Article  CAS  PubMed  Google Scholar 

  113. Serrano PE, Herman JM, Griffith KA, Zalupski MM, Kim EJ, Bekaii-Saab TS, et al. Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014;90(2):270–7.

    Article  CAS  PubMed  Google Scholar 

  114. Cormie P, Spry N, Jasas K, Johansson M, Yusoff IF, Newton RU, et al. Exercise as medicine in the management of pancreatic cancer: a case study. Med Sci Sports Exerc. 2014;46(4):664–70.

    Article  PubMed  Google Scholar 

  115. Yeo TP, Burrell SA, Sauter PK, Kennedy EP, Lavu H, Leiby BE, et al. A progressive postresection walking program significantly improves fatigue and health-related quality of life in pancreas and periampullary cancer patients. J Am Coll Surg. 2012;214(4):463–75; discussion 75–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Hematology/Oncology, NorthShore University HealthSystem, 2650 Ridge Avenue, Evanston, IL, 60213, USA

    Robert de Wilton Marsh M.B., Ch.B., F.A.C.P.

  2. Department of Surgery, NorthShore University HealthSystem, 2650 Ridge Avenue, Evanston, IL, 60213, USA

    Marshall S. Baker M.D., M.B.A., F.A.C.S.

Authors
  1. Robert de Wilton Marsh M.B., Ch.B., F.A.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marshall S. Baker M.D., M.B.A., F.A.C.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert de Wilton Marsh M.B., Ch.B., F.A.C.P. .

Editor information

Editors and Affiliations

  1. Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas, USA

    Matthew H.G. Katz

  2. Division of Surgical Oncology, The University of Cincinnati Medical Center, Cincinnati, Ohio, USA

    Syed A. Ahmad

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

de Wilton Marsh, R., Baker, M.S. (2016). Overview of Multimodality Therapy. In: Katz, M., Ahmad, S. (eds) Multimodality Management of Borderline Resectable Pancreatic Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-22780-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22780-1_5

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22779-5

  • Online ISBN: 978-3-319-22780-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation